Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer

Tamoxifen is the standard endocrine therapy for breast cancers, which require metabolic activation by cytochrome P450 enzymes (CYP). However, the lower and variable concentrations of CYP activity at the tumor ...

Source: Journal of Nanobiotechnology - February 20, 2018 Category: Nanotechnology Authors: Kanchan Chauhan, Juan M. Hernandez-Meza, Ana G. Rodr íguez-Hernández, Karla Juarez-Moreno, Prakhar Sengar and Rafael Vazquez-Duhalt Tags: Research Source Type: research